Literature DB >> 21071774

Gene expression profiles of the oestrogen receptor in breast cancer.

M Kok1, S C Linn.   

Abstract

Breast cancer is a heterogeneous disease and existing clinicopathological classifications do not fully capture the diversity in clinical disease course. Since the oestrogen receptor (ER) plays a central role in the crosstalk between different signalling pathways in breast cancer, the expression of this receptor is important for the behaviour of breast cancer cells and is reflected in gene expression patterns of breast tumours. High throughput analysis of gene expression of breast cancer has increased the insights into ER signalling, including its relation with disease outcome and therapy response. Expression of ER and its numerous downstream targets are driving patterns of gene expression and dominate unsupervised analyses in the breast cancer specimens studied to date, regardless of microarray platform or statistical approach. This paper reviews gene expression studies either attempting to unravel the functional effect of ER or describing the gene expression profiles driven by ER in breast tumours. In addition, the development of molecular signatures predicting response to endocrine treatment will be discussed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21071774

Source DB:  PubMed          Journal:  Neth J Med        ISSN: 0300-2977            Impact factor:   1.422


  4 in total

Review 1.  Assessing estrogen signaling aberrations in breast cancer risk using genetically engineered mouse models.

Authors:  Priscilla A Furth; M Carla Cabrera; Edgar S Díaz-Cruz; Sarah Millman; Rebecca E Nakles
Journal:  Ann N Y Acad Sci       Date:  2011-07       Impact factor: 5.691

2.  Antisense transcript long noncoding RNA (lncRNA) HOTAIR is transcriptionally induced by estradiol.

Authors:  Arunoday Bhan; Imran Hussain; Khairul I Ansari; Sahba Kasiri; Aarti Bashyal; Subhrangsu S Mandal
Journal:  J Mol Biol       Date:  2013-01-31       Impact factor: 5.469

3.  SHON expression predicts response and relapse risk of breast cancer patients after anthracycline-based combination chemotherapy or tamoxifen treatment.

Authors:  Tarek M A Abdel-Fatah; Reuben J Broom; Jun Lu; Paul M Moseley; Baiqu Huang; Lili Li; Suling Liu; Longxin Chen; Runlin Z Ma; Wenming Cao; Xiaojia Wang; Yan Li; Jo K Perry; Mohammed Aleskandarany; Christopher C Nolan; Emad A Rakha; Peter E Lobie; Stephen Y T Chan; Ian O Ellis; Le-Ann Hwang; David P Lane; Andrew R Green; Dong-Xu Liu
Journal:  Br J Cancer       Date:  2019-02-28       Impact factor: 7.640

4.  Differentiation between genetic mutations of breast cancer by breath volatolomics.

Authors:  Orna Barash; Wei Zhang; Jeffrey M Halpern; Qing-Ling Hua; Yue-Yin Pan; Haneen Kayal; Kayan Khoury; Hu Liu; Michael P A Davies; Hossam Haick
Journal:  Oncotarget       Date:  2015-12-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.